Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 1.00 |
| ▸ | HTR2B | P41595 | 9/20 | 1.00 |
| ▸ | HTR2A | P28223 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR1D | P28221 | 5/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5936562 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| SCHEMBL30390274 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| SCHEMBL6094978 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL6092175 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL6093427 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL6095848 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| Maleic Acid SCHEMBL6093195 | 0.90 | HTR2C (0.82) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| Fumaric Acid SCHEMBL6093200 | 0.90 | HTR2C (0.82) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| SCHEMBL6104548 | 0.88 | HTR2C (0.78) | HTR2CHTR2BHTR2AHTR1AHTR1D | |
| SCHEMBL6104539 | 0.88 | HTR2C (0.78) | HTR2CHTR2BHTR2AHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| US-7012090-B1 | such as 1-(2-aminopropyl)-3,7,8,9,-tetrahydro-pyrano-[3,2-e]indol-8-ol | ALCON, INC. (CH) | 2006-03-14 | — | — | US | claimed |
| EP-1268482-B1 | PYRANOINDOLES FOR TREATING GLAUCOMA | ALCON INC (CH) | 2003-09-24 | — | — | EP | claimed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2023081837-A9 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023081837-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220296720-A1 | COMPOSITE CHITOSAN-TANNIN-ACTIVE AGENT COMPOSITIONS AND METHODS OF MAKING AND USING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-09-22 | — | — | US | disclosed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | disclosed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | HTR2C 5/4885HTR2B 15/4885HTR2A 12/4885 |
| US-20220296720-A1 | COMPOSITE CHITOSAN-TANNIN-ACTIVE AGENT COMPOSITIONS AND METHODS OF MAKING AND USING SAME | TTPA, CHIA, CHIT1 | HTR2C 3495/4885HTR2B 3176/4885HTR2A 2918/4885 |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | TTPA, CHIA, CHIT1 | HTR2C 3495/4885HTR2B 3176/4885HTR2A 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.